RHHBY Overview
Upcoming Projects (RHHBY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RHHBY)
-
A Second Look: Discussing the recent label expansion for Genentech's Alecensa (alectinib) as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer.
Ticker: RHHBY
Executed On: Nov 20, 2024 at 04:00 PM EST -
Discussing the potential of Roche's trontinemab for Alzheimers Disease and the data from the Phase Ib/IIa Brainshuttle AD trial presented at CTAD 2024
Ticker: RHHBY
Executed On: Nov 20, 2024 at 03:00 PM EST -
A Third Opinion: Looking at Roche Genentech's topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active lupus nephritis.
Ticker: RHHBY
Executed On: Nov 06, 2024 at 11:30 AM EST -
A Third View: Discussing the recent FDA approval of Ocrevus Zunovo, a new formulation of Ocrevus for multiple sclerosis
Ticker: RHHBY
Executed On: Oct 24, 2024 at 09:45 AM EDT -
A Second View: Discussing the recent FDA approval of Ocrevus Zunovo, a new formulation of Ocrevus for multiple sclerosis
Ticker: RHHBY
Executed On: Oct 23, 2024 at 05:30 PM EDT -
Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Tickers: SRRK, RHHBY, NVS, BIIB
Executed On: Oct 22, 2024 at 06:30 PM EDT -
A Second Opinion: Looking at Roche Genentech's topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active lupus nephritis.
Ticker: RHHBY
Executed On: Oct 15, 2024 at 10:00 AM EDT -
Looking at Roche Genentech's topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active lupus nephritis.
Ticker: RHHBY
Executed On: Oct 09, 2024 at 02:00 PM EDT -
Discussing the recent FDA approval of Ocrevus Zunovo, a new formulation of Ocrevus for multiple sclerosis
Ticker: RHHBY
Executed On: Oct 03, 2024 at 02:00 PM EDT -
Looking at the current treatment landscape and the potential of fenebrutinib, a BTK inhibitor being developed by Roche for the treatment of relapsing multiple sclerosis (RMS).
Ticker: RHHBY
Executed On: Sep 19, 2024 at 05:30 PM EDT -
A Third View: Investigating the potential of CT-996, an oral GLP-1 receptor agonist being developed by Roche for weight loss in obese patients
Ticker: RHHBY
Executed On: Sep 17, 2024 at 01:00 PM EDT -
Dissecting the recent approval of PIASKY (crovalimab), a medication developed by Roche for the treatment of PNH.
Ticker: RHHBY
Executed On: Sep 10, 2024 at 04:30 PM EDT -
A Second View: Investigating the potential of CT-996, an oral GLP-1 receptor agonist being developed by Roche for weight loss in obese patients
Ticker: RHHBY
Executed On: Aug 29, 2024 at 05:15 PM EDT -
Investigating the potential of CT-996, an oral GLP-1 receptor agonist being developed by Roche for weight loss in obese patients
Ticker: RHHBY
Executed On: Aug 28, 2024 at 11:00 AM EDT -
A Third View: Digging into the Phase III Pagoda and Pavilion clinical trial data on Susvimo (ranibizumab injection) in patients with DME
Ticker: RHHBY
Executed On: Aug 22, 2024 at 03:00 PM EDT -
A Second View: Digging into the Phase III Pagoda and Pavilion clinical trial data on Susvimo (ranibizumab injection) in patients with DME
Ticker: RHHBY
Executed On: Aug 22, 2024 at 10:30 AM EDT -
Digging into the Phase III Pagoda and Pavilion clinical trial data on Susvimo (ranibizumab injection) in patients with DME
Ticker: RHHBY
Executed On: Aug 07, 2024 at 04:30 PM EDT -
Discussing the recent label expansion for Genentech's Alecensa (alectinib) as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer.
Ticker: RHHBY
Executed On: Jul 18, 2024 at 10:30 PM EDT -
A Third Opinion: Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo
Tickers: RHHBY, REGN
Executed On: Jul 18, 2024 at 08:15 AM EDT -
A Second Opinion: Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo
Tickers: RHHBY, REGN
Executed On: Jul 15, 2024 at 03:00 PM EDT -
Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo
Tickers: RHHBY, REGN
Executed On: Jul 12, 2024 at 02:00 PM EDT -
A Third Look: Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 23, 2024 at 05:00 PM EDT -
A Second Look: Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 08, 2024 at 09:00 AM EDT -
Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 07, 2024 at 04:30 PM EDT -
A Third Opinion: Discussing the National Institute of Health's Phase III study results of Xolair (omalizumab) for children and adults with food allergies
Ticker: RHHBY
Executed On: Jan 31, 2024 at 11:00 AM EST -
A Second Look: Discussing the current treatment landscape for hepatocellular carcinoma and the use of TECENTRIQ with a prescriber.
Ticker: RHHBY
Executed On: Jan 18, 2024 at 09:00 AM EST -
A Second Opinion: Discussing the National Institute of Health's Phase III study results of Xolair (omalizumab) for children and adults with food allergies
Ticker: RHHBY
Executed On: Jan 11, 2024 at 10:00 AM EST -
Discussing the current treatment landscape for hepatocellular carcinoma and the use of TECENTRIQ with a prescriber.
Ticker: RHHBY
Executed On: Jan 11, 2024 at 07:00 AM EST -
Discussing the National Institute of Health's Phase III study results of Xolair (omalizumab) for children and adults with food allergies
Ticker: RHHBY
Executed On: Jan 10, 2024 at 02:00 PM EST -
A Third Look: Discussing the potential of two medications from Carmot currently in development, CT-388 in obese adults without type 2 diabetes and CT-868 in obese adults with type 2 diabetes
Tickers: RHHBY, Carmot Therapeutics
Executed On: Dec 22, 2023 at 01:30 PM EST -
A Third Look: Investigating the Phase II FENopta study on fenebrutinib, a BTK inhibitor being developed by Roche for the treatment of multiple sclerosis.
Ticker: RHHBY
Executed On: Dec 19, 2023 at 01:00 PM EST -
A Second Look: Investigating the Phase II FENopta study on fenebrutinib, a BTK inhibitor being developed by Roche for the treatment of multiple sclerosis.
Ticker: RHHBY
Executed On: Dec 13, 2023 at 07:00 AM EST -
A Second Look: Discussing the potential of two medications from Carmot currently in development, CT-388 in obese adults without type 2 diabetes and CT-868 in obese adults with type 2 diabetes
Tickers: RHHBY, Carmot Therapeutics
Executed On: Dec 06, 2023 at 03:00 PM EST -
Investigating the Phase II FENopta study on fenebrutinib, a BTK inhibitor being developed by Roche for the treatment of multiple sclerosis.
Ticker: RHHBY
Executed On: Nov 30, 2023 at 12:30 PM EST -
A Third Opinion: Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Tickers: RHHBY, REGN
Executed On: Nov 29, 2023 at 06:00 PM EST -
Discussing the potential of two medications from Carmot currently in development, CT-388 in obese adults without type 2 diabetes and CT-868 in obese adults with type 2 diabetes
Tickers: RHHBY, Carmot Therapeutics
Executed On: Nov 28, 2023 at 01:30 PM EST -
A Third Look: Discussing the FDA approval of Columvi (glofitamab-gxbm) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Ticker: RHHBY
Executed On: Nov 28, 2023 at 11:00 AM EST -
A Second Look: Discussing the FDA approval of Columvi (glofitamab-gxbm) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Ticker: RHHBY
Executed On: Nov 21, 2023 at 07:00 AM EST -
Discussing the FDA approval of Columvi (glofitamab-gxbm) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Ticker: RHHBY
Executed On: Nov 16, 2023 at 03:00 PM EST -
A Second Opinion: Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Tickers: RHHBY, REGN
Executed On: Nov 15, 2023 at 10:00 AM EST -
Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Tickers: RHHBY, REGN
Executed On: Nov 02, 2023 at 09:00 AM EDT -
Discussing the recent results from the Phase 3 CONTACT-02 clinical Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Tickers: RHHBY, EXEL, IPSEY
Executed On: Sep 22, 2023 at 02:00 PM EDT -
A Third Opinion: Discussing Genentech’s Ocrevus (ocrelizumab) to treat patients with multiple sclerosis with a neurologist
Ticker: RHHBY
Executed On: Sep 21, 2023 at 04:00 PM EDT -
A Second Opinion: Discussing Genentech’s Ocrevus (ocrelizumab) to treat patients with multiple sclerosis with a neurologist
Ticker: RHHBY
Executed On: Sep 14, 2023 at 10:00 AM EDT -
A Third Look: Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.
Tickers: OTLK, RHHBY
Executed On: Aug 15, 2023 at 06:15 PM EDT -
A Second Look: Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.
Tickers: OTLK, RHHBY
Executed On: Aug 08, 2023 at 11:00 AM EDT -
Discussing Genentech’s Ocrevus (ocrelizumab) to treat patients with multiple sclerosis with a neurologist
Ticker: RHHBY
Executed On: Jul 18, 2023 at 03:00 PM EDT -
Digging into the Phase 3 NORSE TWO clinical trial of LYTENAVA (bevacizumab-vikg) in patients with wet age-related macular degeneration.
Tickers: OTLK, RHHBY
Executed On: Jul 12, 2023 at 12:00 PM EDT -
A Second Look: Delving into the POLARIX trial data on Roche's Polivy in patients with Diffuse Large B Cell Lymphoma (DLBCL).
Ticker: RHHBY
Executed On: Jun 30, 2023 at 03:05 PM EDT -
Delving into the POLARIX trial data on Roche's Polivy in patients with Diffuse Large B Cell Lymphoma (DLBCL).
Ticker: RHHBY
Executed On: Jun 23, 2023 at 12:30 PM EDT -
A look at the 4 year data on Evrysdi as a treatment for spinal muscular atrophy
Tickers: RHHBY, PTC, NVS
Executed On: May 10, 2023 at 04:00 PM EDT -
A second look: Discussing the recent data presented at the 2023 AACR Conference on Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) in hepatocellular carcinoma.
Ticker: RHHBY
Executed On: Apr 21, 2023 at 11:00 AM EDT -
Discussing the recent data presented at the 2023 AACR Conference on Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) in hepatocellular carcinoma.
Ticker: RHHBY
Executed On: Apr 20, 2023 at 06:00 PM EDT -
A Second Discussion on the recent FDA approval in the US for the first CD20xCD3 bispecific antibody(mosunetuzumab) in adult patients with relapsed or refractory follicular lymphoma
Ticker: RHHBY
Executed On: Apr 12, 2023 at 01:40 PM EDT -
A Discussion on the recent FDA approval in the US for the first CD20xCD3 bispecific antibody(mosunetuzumab) in adult patients with relapsed or refractory follicular lymphoma
Ticker: RHHBY
Executed On: Apr 12, 2023 at 09:00 AM EDT -
A second discussion on EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT, RHHBY, REGN
Executed On: Mar 03, 2023 at 12:30 PM EST -
Discussing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT, RHHBY, REGN
Executed On: Mar 01, 2023 at 05:30 PM EST -
Looking into glofitamab, a bispecific antibody being developed by Roche for the treatment of relapsed or refractory large B-cell lymphoma.
Ticker: RHHBY
Executed On: Feb 08, 2023 at 05:00 PM EST -
A second discussion of the use of Actemra for patients with severe Covid-19 infections in light of its recent FDA approval
Ticker: RHHBY
Executed On: Jan 31, 2023 at 06:00 PM EST -
Reviewing the phase 1/2 clinical trial results of 4D Molecular Therapeutics' 4D-150, a potential gene therapy for patients with wet-AMD
Tickers: FDMT, RHHBY, REGN
Executed On: Jan 24, 2023 at 02:00 PM EST -
Discussing the use of Actemra for patients with severe Covid-19 infections in light of its recent FDA approval
Ticker: RHHBY
Executed On: Jan 12, 2023 at 02:00 PM EST -
An Updated Take on Evrysdi as a treatment for spinal muscular atrophy
Tickers: RHHBY, PTC
Executed On: Nov 03, 2022 at 04:00 PM EDT -
Discussing the P2 acelERA BC study of Giredestrant in patients with ER+, HER2– locally advanced/metastatic breast cancer and the AMEERA-3 Phase 2 study of amcenestrant in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Tickers: SNY, RHHBY, GILD, AZN, DSKYN
Executed On: Oct 04, 2022 at 10:00 AM EDT -
A Second look at the differences between Cimerli anti-VEGF vs Lucentis as therapy for Wet-AMD
Tickers: CHRS, RHHBY
Executed On: Sep 09, 2022 at 12:30 PM EDT -
Discussing the treatment landscape for Huntington's Disease with special attention to PTC 518 and AMT-130
Tickers: QURE, PTCT, IONS, RHHBY
Executed On: Jul 19, 2022 at 08:15 AM EDT -
A Second Look at the Phase 3 SKYSCRAPER-01 study and discussing the potential of TIGIT-targeted drugs
Ticker: RHHBY
Executed On: Jun 22, 2022 at 02:30 PM EDT -
A Look at the Phase 3 SKYSCRAPER-01 study and discussing the potential of TIGIT-targeted drugs
Ticker: RHHBY
Executed On: Jun 16, 2022 at 04:00 PM EDT -
Discussing standard of care for SMA and potential of PTC Therapeutics' Evrysdi
Tickers: PTCT, RHHBY
Executed On: May 25, 2022 at 05:30 PM EDT
Upcoming & Overdue Catalysts (RHHBY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (RHHBY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
